CTIS2023-504715-33-00进行中（未招募）1 期
A Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating theEfficacy and Safety of Guselkumab Administered Subcutaneously in Participants with ActivePsoriatic Arthritis who had an Inadequate Response and/or Intolerance to One Prior Anti-TumorNecrosis Factor a Agent - CNTO1959PSA3005
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 407
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Be at least 18 years of age, Have a diagnosis of PsA for at least 6 months prior to the first administration of study intervention and meet ClASsification criteria for Psoriatic ARthritis criteria at screening., Have active PsA as defined by: a. At least 3 swollen joints and at least 3 tender joints at screening and at baseline AND b. CRP =0.3 mg/dL at screening from the central laboratory. NOTE: A 1-time repeat assessment of CRP level is allowed during the 6-week screening phase and the investigator may consider the participant eligible if the test result is within acceptable range on repeat testing in the central laboratory., Have at least 1 of the following PsA subsets: distal interphalangeal joint involvement, polyarticular arthritis with absence of rheumatoid nodules, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis., Have an inadequate response and/or intolerance to anti-TNFa therapy, defined as presence of active PsA despite previous treatment with one prior anti-TNFa agent. Participants may meet either one or both of the following criteria: a. Lack of benefit of no more than one prior anti-TNFa therapy, as documented in the patient history by the treating physician, after at least 12 weeks of etanercept, adalimumab, golimumab, or certolizumab pegol therapy or at least a 14-week dosage regimen of infliximab. Documented lack of benefit may include inadequate improvement in joint counts, physical function, or disease activity AND/OR b. Intolerance to no more than one prior anti-TNFa therapy, as documented in the patient history by the treating physician, to etanercept, adalimumab, golimumab, certolizumab pegol, or infliximab.
排除标准
- •Has other inflammatory diseases that might confound the evaluations of benefit of guselkumab therapy in the treatment of PsA, including but not limited to rheumatoid arthritis, ankylosing spondylitis/nonradiographic axial spondyloarthritis, systemic lupus erythematosus, or Lyme disease., Has received more than 1 prior anti-TNFa agent., Has received an anti-TNFa agent within the following timeframes: a. Infliximab or golimumab, within 8 weeks prior to the first administration of study intervention. b. Golimumab SC, adalimumab or certolizumab pegol, within 6 weeks prior to the first administration of study intervention. c. Etanercept within 4 weeks prior to the first administration of study intervention., Has previously received any biologic treatment other than an anti-TNFa agent including, but not limited to, guselkumab, ustekinumab, secukinumab, tildrakizumab, ixekizumab,brodalumab, risankizumab or other investigative biologic treatment.
研究者
相似试验
进行中（未招募）
1 期
A Phase 3B, study of Guselkumab in Participants with ActivePsoriatic Arthritis who had an Inadequate Response and/or Intolerance to One Prior Anti-Tumor Necrosis Factor a AgentMedDRA version: 21.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859Psoriatic ArthritisEUCTR2021-000482-32-HUJanssen-Cilag International NV450
进行中（未招募）
1 期
A Phase 3B, study of Guselkumab in Participants with ActivePsoriatic Arthritis who had an Inadequate Response and/or Intolerance to One Prior Anti-Tumor Necrosis Factor a AgentPsoriatic ArthritisMedDRA version: 21.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2021-000482-32-PLJanssen-Cilag International NV450
进行中（未招募）
1 期
A Phase 3B, study of Guselkumab in Participants with ActivePsoriatic Arthritis who had an Inadequate Response and/or Intolerance to One Prior Anti-Tumor Necrosis Factor a AgentPsoriatic ArthritisMedDRA version: 21.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2021-000482-32-BGJanssen-Cilag International NV450
进行中（未招募）
1 期
A Study of the Efficacy and Safety of Guselkumab in Participants with Active Psoriatic ArthritisPsoriatic arthritis (PsA)MedDRA version: 21.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859EUCTR2020-004981-20-HRJanssen-Cilag International NV950
进行中（未招募）
1 期
A Study of the Efficacy and Safety of Guselkumab in Participants with Active Psoriatic ArthritisPsoriatic arthritis (PsA)MedDRA version: 21.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859EUCTR2020-004981-20-SIJanssen-Cilag International NV950